<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644124</url>
  </required_header>
  <id_info>
    <org_study_id>TCD10173</org_study_id>
    <secondary_id>EudraCT 2007-003737-16</secondary_id>
    <nct_id>NCT00644124</nct_id>
  </id_info>
  <brief_title>Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma</brief_title>
  <official_title>A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the selected dose of aflibercept when it is
      combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone
      +/- intrathecal Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin
      B-cell lymphoma, and to determine how the body handles aflibercept when it is administered
      with R-CHOP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>selected dose of aflibercept based on Dose Limiting Toxicities observed</measure>
    <time_frame>cycle 1 +/- 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>cycle 2, 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Aflibercept RCHOP 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept RCHOP 21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>in combination with standard treatment R-CHOP</description>
    <arm_group_label>Aflibercept RCHOP 14</arm_group_label>
    <arm_group_label>Aflibercept RCHOP 21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-Hodgkin B-cell lymphoma, good condition, not previously treated

        Exclusion Criteria:

          -  Contraindication to any drug contained in the R-CHOP
             (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal
             Methotrexate)

          -  Less than 42 days elapsed from prior major surgery (28 days from other prior surgery)
             to the time of inclusion

          -  Cerebral or leptomeningeal involvement.

          -  History of another neoplasm (Adequately treated basal cell or squamous cell skin
             cancers, carcinoma in situ of the cervix, or any other cancer from which the patient
             has been disease free for &gt; 5 years are allowed)

          -  Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to the first drug intake

          -  Any acute or chronic medical condition, which could impair the ability of the patient
             to participate to the study or could interfere with interpretation of study results

          -  Uncontrolled diabetes mellitus

          -  Uncontrolled hypertension

          -  Abnormal kidney function

          -  Evidence of clinically significant bleeding diathesis, non-healing wound or underlying
             coagulopathy

          -  Pregnant or breast-feeding woman, or patient with reproductive potential (male,
             female) without an effective method of contraception

          -  History of hypersensitivity to any Trap agents or recombinant proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etudes du Lymphome de l'Adulte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>angiogenesis inhibitors</keyword>
  <keyword>CHOP protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

